Ended 2022 with cash, cash equivalents, and marketable securities of $120.5M. "Following the very encouraging results from our Phase 2 CANAL trial in IPF chronic cough, we have entered a transformational period in the development of Haduvio for the treatment of serious chronic cough conditions," said Jennifer Good, CEO of Trevi Therapeutics. "With a strong balance sheet and cash runway expected into 2026, we are well-positioned to develop Haduvio as a pipeline in a product, supported by the differentiated central and peripheral mechanism of action of Haduvio."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TRVI:
